Dealing with the most common side effect of statins
DOI:
https://doi.org/10.12775/JEHS.2023.31.01.001Keywords
cardiovascular risk, dyslipidemia, LDL, intoleranceAbstract
Statins are one of the key drugs in the treatment of cardiology patients. They lower LDL cholesterol levels, thereby reducing the risk of acute cardiovascular events. Statins are among the best studied drugs, and have been proven to be effective and safe in the treatment of dyslipidemia. Data presented in studies on the prevalence of statin intolerance (SI) varies widely, according to some studies, statin tolerance is the same as placebo, however, this is a common problem in clinical practice. The most common reported symptoms of SI include muscle pain. Patients are often afraid of starting satin treatment because of possible side effects. The appearance of myopathy in patients results in their discontinuation of therapy, which results in increased cardiovascular risk. In order to minimize the risk of SI, particularly statin-associated muscular pain (SI), a key role is played by discussion with the patient, exclusion of nocebo effects, identification of risk factors, dose modification and possible discontinuation of the drug. The purpose of this paper is to review the problem of the most common of the adverse effects of statins- myopathy, in terms of incidence, probable cause, and recommended treatment of patients.
References
Attardo, S., Musumeci, O., Velardo, D., & Toscano, A. (2022). Statins Neuromuscular Adverse Effects. In International Journal of Molecular Sciences (Vol. 23, Issue 15).
Pohjola-Sintonen, S.; Julkunen, H. Muscle-related adverse effects of statins. Duodecim 2014,130, 1622–1627.
Abd, T.T.; Jacobson, T.A. Statin-induced myopathy: A review and update. Expert Opin. Drug Saf. 2011,10, 373–387
Abed, W.; Abujbara, M.; Batieha, A.; Ajlouni, K. Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Ann. Med. Surg. 2022,74, 103304.
Alonso, R.; Cuevas, A.; Cafferata, A. Diagnosis and Management of Statin Intolerance.J. Atheroscler. Thromb.2019,26, 207–215
Laufs U, Weingärtner O, Kassner U, Schatz U. State of the Art: Therapie mit Statinen [State of the Art: Statin Therapy]. Dtsch Med Wochenschr. 2022 Jan;147(1-02):62-68.
Stürzebecher PE, Schumann F, Kassner U, Laufs U. Statinintoleranz und statinassoziierte Muskelschmerzen [Statin intolerance and statin-associated muscular pain]. Herz. 2022 Jun;47(3):204-211.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207.
Collins R, Reith C, Emberson J, et. Al.. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532-2561.
Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81.
Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C.
Armitage J. The safety of statins in clinical practice. Lancet. 2007 Nov 24;370(9601):1781-90.
US Food and Drug Administration. FDA Drug Safety Communication December 2011: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/ DrugSafety/ucm256581.htm (accessed 15.04.2023).
SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomized trial. Lancet 2010; 376: 1658–69
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22
Prieto-Merino D, Smeeth L, Staa TP, Roberts I. Dangers of non-specific composite outcome measures in clinical trials. BMJ 2013; 347: f6782.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Martyna Janczewska, Maria Kalicka, Małgorzata Piekarska, Radosław Kasperski, Joanna Kobak, Jakub Gryta, Karolina Iwan, Tomasz Krysa

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 556
Number of citations: 0